title: [Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of MHSP65-TCL on melanoma and its effect on the activity of the immunocytes.
  
  
  METHODS
  MHSP65-TCL was prepared by mixing MHSP65 with TCL derived from B16 melanoma cell lysate by repeated freezing and thawing. The MHSP65-TCL vaccine was administered in mice bearing B16 melanoma, and the changes in melanoma growth was observed. To investigate the influence of TCL in MHSP65-TCL on the activity of the immunocytes, we co-cultured TCL and mouse spleen cells in vitro, and analyzed CD69 expression on the cells, cell apoptosis, and levels of IL-10 and IFN-γ in the cell culture supernatant.
  
  
  RESULTS
  The MHSP65-TCL vaccine showed an anti-melanoma effect in the tumor-bearing mice. In the in vitro experiment, TCL in MHSP65-TCL strongly stimulated the activation of mouse spleen cells while causing apoptosis in some of the immunocytes and promoting cellular IL-10 secretion, but not IFN-γ.
  
  
  CONCLUSIONS
  MHSP65-TCL derived from B16 melanoma cells has an anti-melanoma effect mediated by the activation of immunocytes. TCL in MHSP65-TCL also has immunosuppressive effect on immunocytes possibly due to the presence of suppressive components in TCL, and identifying and eliminating these components may potentially improve the anti-tumor actovoty of MSHP65-TCL vaccine.
authors.affiliation: School of Basic Medicine, Wannan Medical College, Wuhu 241002, China.E-mail: 240151563@ qq.com.
authors.forename: Bohan
authors.initials: B
authors.lastname: Dong
authors.forename: Guangli
authors.initials: G
authors.lastname: Dai
authors.forename: Zhilin
authors.initials: Z
authors.lastname: Qi
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Jun
authors.initials: J
authors.lastname: Lu
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D017209:Apoptosis; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology*; D019496:Cancer Vaccines; D002457:Cell Extracts / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D018834:Chaperonin 60 / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D037181:Lectins, C-Type / Q000378:metabolism; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D013154:Spleen / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D047368:Tumor Burden / Q000276:immunology; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D001426:Bacterial Proteins; D019496:Cancer Vaccines; D002457:Cell Extracts; D018834:Chaperonin 60; D007371:Interferon-gamma; D016753:Interleukin-10; D037181:Lectins, C-Type; D000099192:CD69 Antigens; C074119:heat-shock protein 65, Mycobacterium